Hyperoxia Induced Pulmonary Inflammation and Organ Injury: a Human in Vivo Model
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Oxygen is the most commonly administered therapy in critical illness. Accumulating evidence
suggests that patients often achieve supra-physiological levels of oxygenation in the
critical care environment. Furthermore, hyperoxia related complications following cardiac
arrest, myocardial infarction and stroke have also been reported. The underlying mechanisms
of hyperoxia mediated injury remain poorly understood and there are currently no human in
vivo studies exploring the relationship between hyperoxia and direct pulmonary injury and
inflammation as well as distant organ injury.
The current trial is a mechanistic study designed to evaluate the effects of prolonged
administration of high-flow oxygen (hyperoxia) on pulmonary and systemic inflammation. The
study is a randomised, double-blind, placebo-controlled trial of high-flow nasal oxygen
therapy versus matching placebo (synthetic medical air). We will also incorporate a model of
acute lung injury induced by inhaled endotoxin (LPS) in healthy human volunteers. Healthy
volunteers will undergo bronchoalveolar lavage (BAL) at 6 hours post-intervention to enable
measurement of pulmonary and systemic markers of inflammation, oxidative stress and cellular
injury.